Longeveron vs Cartesian Therapeutics
Cartesian Therapeutics is the larger business, with $2.8m of revenue in fiscal 2025 against $1.2m for Longeveron (2.3 times as much). Longeveron grew faster (-49.9% against -92.8%). Longeveron kept more of each dollar of sales as profit: a net margin of -1893.6% against -4658.6%.
| Latest fiscal year | LongeveronLGVN, 2025 | Cartesian TherapeuticsRNAC, 2025 |
|---|---|---|
| Revenue | $1.2m | $2.8m |
| Revenue growth | -49.9% | -92.8% |
| Net income | −$22.7m | −$130m |
| Operating margin | -1942.2% | -5127.1% |
| Net margin | -1893.6% | -4658.6% |
| Return on equity | -164.7% | — |
| Free cash flow | −$18.9m | −$79.4m |
| Cash | $4.7m | $125m |
| Total debt | $0 | $0 |
| Debt to equity | 0.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 37 | 75 |
| Market value | $55.5m | $193m |
| Price vs our value range | — | — |
| Moat score | 19 (Weak) | 9 (Weak) |
| Insider trades, 12 months | 0 buys, 0 sales | 1 buys, 3 sales |